Bruce Jacobs's Insider Trades & SAST Disclosures
Bruce Jacobs's most recent trade in Kymera Therapeutics Inc was a trade of 60,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Bruce Jacobs.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 30,000 | 208,921 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.33 per share. | 03 Mar 2025 | 5,754 | 203,167 | - | 30.3 | 174,502 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.00 per share. | 03 Mar 2025 | 1,281 | 201,886 | - | 31.0 | 39,717 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 10 Jan 2025 | 10,000 | 178,921 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2025 | 10,000 | 94,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 27 Jun 2024 | 25,000 | 168,554 | - | 2.1 | 52,000 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2024 | 25,000 | 104,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 187,500 | 187,500 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 31,250 | 146,285 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.41 per share. | 01 Mar 2024 | 2,378 | 143,907 | - | 41.4 | 98,481 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.39 per share. | 01 Mar 2024 | 1,301 | 142,606 | - | 42.4 | 55,153 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 43.25 per share. | 01 Mar 2024 | 255 | 142,351 | - | 43.3 | 11,030 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 02 Jun 2023 | 10,000 | 115,035 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2023 | 10,000 | 129,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 142,500 | 142,500 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 23,750 | 105,938 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.88 per share. | 01 Mar 2023 | 1,056 | 104,882 | - | 30.9 | 32,607 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.40 per share. | 01 Mar 2023 | 314 | 104,568 | - | 31.4 | 9,859 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 21 Oct 2022 | 10,000 | 81,279 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2022 | 10,000 | 139,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 17 Oct 2022 | 10,000 | 71,279 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 10,000 | 149,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 20,000 | 159,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 May 2022 | 20,000 | 60,814 | - | 2.1 | 41,600 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 13,300 | 40,814 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 14 Jan 2022 | 10,000 | 27,514 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 10,000 | 179,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 12 Jan 2022 | 15,000 | 32,514 | - | 2.1 | 31,200 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2022 | 15,000 | 36,974 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 52.13 per share. | 12 Jan 2022 | 7,151 | 18,936 | - | 52.1 | 372,788 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 51.21 per share. | 12 Jan 2022 | 6,427 | 26,087 | - | 51.2 | 329,149 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 53.27 per share. | 12 Jan 2022 | 1,422 | 17,514 | - | 53.3 | 75,747 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2021 | 10,000 | 199,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 23 Nov 2021 | 10,000 | 17,256 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2021 | 10,000 | 209,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 Sep 2021 | 10,000 | 17,256 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.05 per share. | 03 Sep 2021 | 8,500 | 8,756 | - | 60.1 | 510,436 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.50 per share. | 03 Sep 2021 | 1,500 | 7,256 | - | 60.5 | 90,744 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 10,000 | 219,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 Jun 2021 | 10,000 | 17,256 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 46.66 per share. | 03 Jun 2021 | 5,506 | 11,494 | - | 46.7 | 256,905 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 47.13 per share. | 03 Jun 2021 | 4,494 | 7,256 | - | 47.1 | 211,790 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 7,000 | 229,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 13 Apr 2021 | 7,000 | 7,000 | - | 2.1 | 14,560 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2021 | 8,195 | 234,061 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.17 per share. | 11 Mar 2021 | 8,195 | 0 | - | 60.2 | 493,096 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 11 Mar 2021 | 8,195 | 8,195 | - | 2.1 | 17,046 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 11 Mar 2021 | 1,805 | 1,805 | - | 2.1 | 3,754 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2021 | 1,805 | 242,256 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.07 per share. | 11 Mar 2021 | 1,805 | 0 | - | 60.1 | 108,432 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2021 | 10,000 | 244,061 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 08 Mar 2021 | 10,000 | 10,000 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 50.46 per share. | 08 Mar 2021 | 7,699 | 2,301 | - | 50.5 | 388,482 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 51.28 per share. | 08 Mar 2021 | 2,300 | 1 | - | 51.3 | 117,936 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 52.00 per share. | 08 Mar 2021 | 1 | 0 | - | 52 | 52 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2021 | 20,000 | 254,061 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 Mar 2021 | 20,000 | 20,000 | - | 2.1 | 41,600 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 45.07 per share. | 03 Mar 2021 | 12,019 | 1,100 | - | 45.1 | 541,700 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 44.12 per share. | 03 Mar 2021 | 6,881 | 13,119 | - | 44.1 | 303,611 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 45.75 per share. | 03 Mar 2021 | 1,100 | 0 | - | 45.7 | 50,323 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2020 | 32,904 | 32,904 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges